NASDAQ:TRAX

First Tracks Biotherapeutics (TRAX) Stock Price, News & Analysis

$46.56 -0.54 (-1.15%)
Closing price 04:00 PM Eastern
Extended Trading
$46.50 -0.06 (-0.13%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About First Tracks Biotherapeutics Stock (NASDAQ:TRAX)

Advanced

Key Stats

Today's Range
$46.28
▼
$48.48
50-Day Range
$30.59
▼
$52.33
52-Week Range
$14.72
▼
$54.78
Volume
438,193 shs
Average Volume
718,417 shs
Market Capitalization
$1.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.17
Consensus Rating
Moderate Buy

Company Overview

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

First Tracks Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

TRAX MarketRank™: 
3.581970482645 of 5 stars

First Tracks Biotherapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 192nd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    First Tracks Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    First Tracks Biotherapeutics has a consensus price target of $72.17, representing about 55.0% upside from its current price of $46.56.

  • Amount of Analyst Coverage

    First Tracks Biotherapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about First Tracks Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for First Tracks Biotherapeutics are expected to grow in the coming year, from ($4.24) to ($3.80) per share.

  • Price to Book Value per Share Ratio

    First Tracks Biotherapeutics has a P/B Ratio of 12.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    12.03% of the float of First Tracks Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    First Tracks Biotherapeutics has a short interest ratio ("days to cover") of 6.52.
  • Change versus previous month

    Short interest in First Tracks Biotherapeutics has recently decreased by 27.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    First Tracks Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    First Tracks Biotherapeutics does not have a long track record of dividend growth.

  • News Sentiment

    First Tracks Biotherapeutics has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for First Tracks Biotherapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for TRAX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added First Tracks Biotherapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, First Tracks Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,758,287.00 in company stock.

  • Percentage Held by Institutions

    First Tracks Biotherapeutics has minimal institutional ownership at this time.

  • Read more about First Tracks Biotherapeutics' insider trading history.
Receive TRAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for First Tracks Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRAX Stock News Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Headlines

TRAX Stock Analysis - Frequently Asked Questions

First Tracks Biotherapeutics' stock was trading at $17.00 on April 21, 2026. Since then, TRAX shares have increased by 173.9% and is now trading at $46.56.

First Tracks Biotherapeutics (NASDAQ:TRAX) announced its quarterly earnings data on Tuesday, November, 3rd. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04.

Top institutional shareholders of First Tracks Biotherapeutics include State Street Corp (3.83%), Soleus Capital Management L.P. (0.33%), Marshall Wace LLP (0.21%) and HighVista Strategies LLC (0.17%).
View institutional ownership trends
.

Shares of TRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/03/2026
Today
11/16/2026
Jefferies Global Healthcare Conference
11/16/2026
UBS Global Biopharma Conference 2026
11/17/2026
38th Annual Healthcare Conference
12/01/2026
9th Annual Evercore ISI HealthCONx Conference
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:TRAX
CIK
2091349
Fax
N/A
Employees
104
Year Founded
N/A

Price Target and Rating

High Price Target
$110.00
Low Price Target
$31.00
Potential Upside/Downside
+55.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.16
Quick Ratio
9.16

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.59 per share
Price / Book
12.97

Miscellaneous

Outstanding Shares
42,020,000
Free Float
N/A
Market Cap
$1.96 billion
Optionable
Optionable
Beta
N/A
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:TRAX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners